CYANIDIN CHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H11O6.Cl
Molecular Weight	322.697
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Cl-].OC1=CC(O)=C2C=C(O)C(=[O+]C2=C1)C3=CC(O)=C(O)C=C3

InChI

InChIKey=COAWNPJQKJEHPG-UHFFFAOYSA-N

InChI=1S/C15H10O6.ClH/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7;/h1-6H,(H4-,16,17,18,19,20);1H

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28788070 | https://www.ncbi.nlm.nih.gov/pubmed/28771720 | https://www.ncbi.nlm.nih.gov/pubmed/28722162

Cyanidin is a natural anthocyanidin present in fruits and vegetables, attenuates the development of several diseases, including asthma, diabetes, atherosclerosis, and cancer, through its anti-inflammatory effects. Its mechanism of action is still undefined, but it was revealed that cyanidin specifically recognizes an IL-17A binding site in the IL-17A receptor subunit (IL-17RA) and inhibits the IL-17A/IL-17RA interaction and thus can be used as a drug for the treatment of IL-17A-dependent inflammatory diseases and cancer. In addition, cyanidin was capable of inhibiting osteoclast formation and thus might have therapeutic potential for osteolytic diseases.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Interleukin-17 receptor A 2 Target ID: Q96F46 Gene ID: 23765.0 Gene Symbol: IL17RA Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/28223414	Binding Agent 1064		3.0 µM [Kd]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Osteolytic diseases 2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28771720	Primary		Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Cyanidin Stimulates Insulin Secretion and Pancreatic β-Cell Gene Expression through Activation of l-type Voltage-Dependent Ca(2+) Channels.	2017 Jul 28	28788070

Patents

Sample Use Guides

In Vivo Use Guide

in mice: To examine the effect of A18 (also called cyanidin) on IL-17A–induced epidermal cell proliferation, it was intradermally injected the ears of female WT C57BL/6 mice with PBS or with IL-17A alone or together with A18 for six consecutive days. After the injections, the mice treated with IL-17 alone exhibited IL-17A–dependent epidermal hyperplasia, whereas the mice treated with both IL-17 and A18 exhibited reduced hyperplasia.

Route of Administration: Other

In Vitro Use Guide

It was studied the mechanisms of cyanidin for stimulatory insulin secretion from pancreatic β-cells. Cyanidin (1–300 µM) stimulated insulin secretion and cyanidin (80 to 300 µM) increased intracellular Ca2+ signals in a concentration-dependent manner. The Ca2+ signals were abolished by nimodipine, an l-type voltage-dependent Ca2+ channel (VDCC) blocker or under extracellular Ca2+ free conditions. Stimulation of cells with cyanidin activated currents typical for VDCCs and up-regulated the expression of glucose transporter 2 (GLUT2), Kir6.2, and Cav1.2 genes.

Name

Type

Language

CYANIDIN CHLORIDE

Common Name

English

3,3',4',5,7-PENTAHYDROXY-2-PHENYLBENZOPYRYLIUM CHLORIDE

Common Name

English

1-BENZOPYRYLIUM, 2-(3,4-DIHYDROXYPHENYL)-3,5,7-TRIHYDROXY-, CHLORIDE

Systematic Name

English

CYANIDOL CHLORIDE

Common Name

English

3,3',4',5,7-PENTAHYDROXYFLAVYLIUM CHLORIDE

Systematic Name

English

1-BENZOPYRYLIUM, 2-(3,4-DIHYDROXYPHENYL)-3,5,7-TRIHYDROXY-, CHLORIDE (1:1)

Systematic Name

English

IDB-1027

Code

English

CYANIDIN CHLORIDE [USP-RS]

Common Name

English

CYANIDIN CHLORIDE [MI]

Common Name

English

2-(3,4-DIHYDROXYPHENYL)-3,5,7-TRIHYDROXY-1-BENZOPYRYLIUM CHLORIDE

Systematic Name

English

NSC-407291

Code

English

FLAVYLIUM, 3,3',4',5,7-PENTAHYDROXY-, CHLORIDE

Systematic Name

English

Code System Code Type Description

RS_ITEM_NUM

1151924